Managing Pulmonary Embolism Posthospital Discharge

Slides:



Advertisements
Similar presentations
The EINSTEIN PE Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Pulmonary Embolism.
Advertisements

Neue Antikoagulantien bei spontaner und Tumor-assoziierter VTE Paul Kyrle Univ. Klinik f. Innere Medizin I AKH/Medizinische Universität Wien.
The EINSTEIN DVT Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Deep Vein Thrombosis.
EINSTEIN DVT and EINSTEIN PE Pooled Analysis
The EINSTEIN EXT Study 'Xarelto' for the Long-Term Prevention of Recurrent Venous Thromboembolism.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?
Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin,
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
Ryan Sparks, PharmD, BCPS PGY2 Cardiology Resident
Addressing the Challenges in Primary and Secondary Stroke Prevention
Covering the Bases in Cardioversion
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
NOACs for Cancer-Associated Thrombosis:
Extended Treatment of VTE: Who is the Right Candidate?
NOACs In Long-term VTE Treatment: A State Of The Art Review
Long-Term Treatment of VTE: Case Studies
US Guidelines US Guidelines Low-risk Patients.
Thrombosis, Cancer, and NOACs
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
New Strategies to Prevent CV Events After Hospital Discharge
Emergency Management of NOAC Bleeding
A New Era for NOACs:.
Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.
The Safety and Efficacy of Full vs
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
New Perspectives in CAD and PAD: Weighing the Latest Evidence
Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
A Case Challenge: Anticoagulant Choices for Acute PE
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
The Essentials for Secondary Stroke Prevention
Timing the First Postoperative Dose of Anticoagulants
New Oral Anticoagulants and VTE Management
VTE Treatment Conventional Approach
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
Access to NOAC Therapy:
Antithrombotic Protection in CAD and HF
Learning Objectives Classification of VTE Goals of VTE Treatment.
Timing the First Postoperative Dose of Anticoagulants
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Dos and Don’ts for High-Risk Elderly Patients With AF
Extending Treatment for Thrombosis: What’s the Right Choice?
Practical Considerations to Extend Treatment for VTE
Extraordinary Cases of VTE Prevention in Patients With Cancer
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Anticoagulation and Thrombosis Management
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Long-Term Treatment of VTE: Case Studies
Factor Xa Inhibitors in PAD
A Time for Change for Managing Patients With VTE Who Have Cancer
Cancer-Associated Thrombosis
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
NOAC Studies in VTE AF Studies Superior Outcomes.
Extraordinary Cases in VTE
Program Goals Background: Anticoagulation in Patients With VTE.
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
5 Good Minutes on Atrial Fibrillation-related Stroke
At the Crossroads of Coagulation
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Treating Pulmonary Embolism Today
Translating Data From Trial to Practice
Presentation transcript:

Managing Pulmonary Embolism Posthospital Discharge

Burden of VTE

Phases of VTE Treatment

NOAC Doses in Acute VTE Treatment Trials

Efficacy and Safety of NOACs: Meta-Analysis of Acute VTE Treatment Trials

EINSTEIN-PE: Treatment of Acute Symptomatic PE

Phase III Acute VTE Studies With NOACs: Subgroup With Index PE ± DVT

VTE Extension Trials: Efficacy and Safety Outcomes

EINSTEIN CHOICE: Study Design

EINSTEIN CHOICE: Primary Outcome -- Recurrent VTE

EINSTEIN CHOICE: Bleeding Outcomes

Extended Treatment: NNTB

Risk of VTE Recurrence: Based on Type of VTE Event

VTE Provoked by Surgery: Risk of Recurrence

VTE Provoked by Nonsurgical Transient Risk Factors: Risk of Recurrence

Unprovoked VTE: Risk of Recurrence

Benefit/Risk of Extended Treatment

Era of NOACs: Shift in Extended Anticoagulation

VTE Treatment Phases: Anticoagulant Dosing in the Era of NOACs

Approach to Improving Medication Adherence

INSPIRE: Aspirin for Prevention of Recurrent VTE

Extended VTE Treatment in the Era of NOACs

PE Home Treatment: 2016 CHEST Guidelines

Post-PE Care: Follow-Up in the First Year

Summary

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.